DSG1 (Desmoglein-1) variants and mutations
DSG1 (also known as Desmoglein-1) is a human protein-coding gene encoding a desmoglein-1 protein. It provides strong desmosomal adhesion in the superficial epidermis and helps maintain skin-barrier integrity under mechanical stress. Pathogenic variants can cause palmoplantar keratoderma or severe dermatitis, while autoantibodies against it cause pemphigus foliaceus. This analysis covers 1,651 DSG1 variants and mutations. Of these, 92% have computational variant effect predictions. Disease context includes severe dermatitis-multiple allergies-metabolic wasting syndrome, palmoplantar keratoderma i, striate, focal, or diffuse, and striate palmoplantar keratoderma. Example DSG1 variants include D2G, D2H, and D2N.
Variant analysis overview
- Gene: DSG1
- Protein: Desmoglein-1
- UniProt accession: Q02413
- Organism: Homo sapiens
- Variants analyzed: 1651
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 1,473 unspecified-consequence records; 95 missense variants; 74 synonymous variants; 7 frameshift variants; 3 splice-region variants; 1 stop-gained variants
- Prediction scores: 1,522 variants have prediction scores (92% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: severe dermatitis-multiple allergies-metabolic wasting syndrome, palmoplantar keratoderma i, striate, focal, or diffuse, striate palmoplantar keratoderma, hereditary palmoplantar keratoderma, epidermolytic palmoplantar keratoderma, 1, Palmoplantar keratoderma, diffuse palmoplantar keratoderma with painful fissures, focal palmoplantar keratoderma with joint keratoses, dermatophytosis, epidermal disease, Diffuse palmoplantar hyperkeratosis, Abnormality of the skin.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 4 domains; 4 post-translational modification sites.
- Structural context: 721 variants have structural context.
- PTM context: 8 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable DSG1 variants
Examples include D2G, D2H, D2N, W3C, W3R, S4N, F6L, R7G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- D2G (p.Asp2Gly), 1000Genomes rs189796357, ExAC rs189796357
- D2H (p.Asp2His), rs2511038285, ClinGen CA402127287, NCI-TCGA Cosmic COSV9993, Uncertain significance, not provided
- D2N (p.Asp2Asn), NCI-TCGA Cosmic COSV9993, MetaLR 0.12, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- W3C (p.Trp3Cys), rs762299574, ClinGen CA8925720, ClinVar RCV002003276, ExAC rs762299574, REVEL 0.39, MetaLR 0.38, Uncertain significance, not provided
- W3R (p.Trp3Arg), TOPMed rs1351444524, REVEL 0.48, MetaLR 0.36
- S4N (p.Ser4Asn), ExAC rs767924353, gnomAD rs767924353, REVEL 0.12, MetaLR 0.06
- F6L (p.Phe6Leu), gnomAD 18-31318316-T-C, REVEL 0.06, MetaLR 0.10
- R7G (p.Arg7Gly), rs150439970, ClinGen CA8925722, ClinVar RCV002637153, ESP rs150439970, REVEL 0.14, MetaLR 0.18, Uncertain significance, not provided
- R7T (p.Arg7Thr), TOPMed rs1237128145
- R7R (p.Arg7Arg), gnomAD 18-31318319-A-C, CADD 6.87
- V8I (p.Val8Ile), rs1331948792, gnomAD rs1331948792, REVEL 0.05, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- V8G (p.Val8Gly), gnomAD 18-31318323-T-G, REVEL 0.07, MetaLR 0.10
- V8A (p.Val8Ala), gnomAD 18-31318323-T-C, REVEL 0.04, MetaLR 0.07
- V9A (p.Val9Ala), gnomAD 18-31318326-T-C, REVEL 0.11, MetaLR 0.05
- V9D (p.Val9Asp), gnomAD 18-31318326-T-A, REVEL 0.15, MetaLR 0.13
- V9V (p.Val9Val), rs966556033, gnomAD 18-31318327-T-C, CADD 5.58
- A10G (p.Ala10Gly), TOPMed rs1303877798, MetaLR 0.10, MetaSVM -1.06
- A10V (p.Ala10Val), gnomAD 18-31318329-C-T, REVEL 0.07, MetaLR 0.14
- A10A (p.Ala10Ala), rs760929884, gnomAD 18-31318330-A-G, CADD 1.18
- M11I (p.Met11Ile), Ensembl rs1598693320, REVEL 0.05, MetaLR 0.06
- M11V (p.Met11Val), rs1426310, ClinGen CA8925724, ClinVar RCV000455447, ClinVar RCV001520702, REVEL 0.07, MetaLR 0.00, Benign, not provided; Severe dermatitis-multiple allergies-metabolic wasting syndrome; n
- M11T (p.Met11Thr), gnomAD 18-31318332-T-C, REVEL 0.05, MetaLR 0.07
- L12Q (p.Leu12Gln), gnomAD rs1489241705, REVEL 0.37, MetaLR 0.33
- F13S (p.Phe13Ser), gnomAD rs2071633017, REVEL 0.12, MetaLR 0.12
- F13L (p.Phe13Leu), gnomAD 18-31318339-C-A, REVEL 0.03, MetaLR 0.06
- I14F (p.Ile14Phe), rs141269991, ClinGen CA8925725, ClinVar RCV002110865, ClinVar RCV005370167, REVEL 0.12, MetaLR 0.16, Benign/Likely benign, Severe dermatitis-multiple allergies-metabolic wasting syndrome; not provided
- I14V (p.Ile14Val), rs141269991, ClinGen CA402127370, ClinVar RCV002299993, REVEL 0.06, MetaLR 0.12, Uncertain significance, not provided
- I14T (p.Ile14Thr), gnomAD 18-31318341-T-C, REVEL 0.07, MetaLR 0.16
- I14I (p.Ile14Ile), gnomAD 18-31318342-T-A, CADD 9.00
- F15I (p.Phe15Ile), gnomAD 18-31318343-T-A, REVEL 0.07, MetaLR 0.16
- F15L (p.Phe15Leu), gnomAD 18-31318343-T-C, REVEL 0.07, MetaLR 0.08
- F15C (p.Phe15Cys), gnomAD 18-31318344-T-G, REVEL 0.06, MetaLR 0.14
- L16V (p.Leu16Val), ExAC rs755031242, gnomAD rs755031242, REVEL 0.08, MetaLR 0.08
- L16W (p.Leu16Trp), gnomAD 18-31318340-AT-A, CADD 23.80
- V17=, rs1315633822, NCI-TCGA Cosmic COSV9993, Variant assessed as somatic; low impact.
- V17A (p.Val17Ala), rs2511042423, ClinGen CA402127401, ClinVar RCV003877083, REVEL 0.27, MetaLR 0.32, Uncertain significance, not provided
- V17M (p.Val17Met), ExAC rs773601716, gnomAD rs773601716, REVEL 0.19, MetaLR 0.31
- V17L (p.Val17Leu), gnomAD 18-31326581-G-T, REVEL 0.13, MetaLR 0.18
- V18L (p.Val18Leu), gnomAD 18-31326584-G-T, REVEL 0.08, MetaLR 0.13
- V18E (p.Val18Glu), gnomAD 18-31326585-T-A, REVEL 0.24, MetaLR 0.27
- V19* (p.Val19Ter), gnomAD 18-31326585-TG-T, CADD 23.10
- V19I (p.Val19Ile), gnomAD 18-31326587-G-A, REVEL 0.05, MetaLR 0.10
- V19V (p.Val19Val), rs760980973, gnomAD 18-31326589-A-G, CADD 6.06
- E20D (p.Glu20Asp), TOPMed rs1305771244, MetaLR 0.11, MetaSVM -1.00
- V21I (p.Val21Ile), NCI-TCGA TCGA novel, MetaLR 0.11, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- N22K (p.Asn22Lys), gnomAD 18-31326598-C-A, REVEL 0.09, MetaLR 0.16
- S23G (p.Ser23Gly), gnomAD rs1430240324, REVEL 0.08, MetaLR 0.13
- S23N (p.Ser23Asn), NCI-TCGA Cosmic COSV9993, REVEL 0.17, MetaLR 0.21, Uncertain significance, not provided
- S23S (p.Ser23Ser), gnomAD 18-31326601-T-C, CADD 9.70
- E24* (p.Glu24Ter), TOPMed rs1235063801, gnomAD rs1235063801, CADD 43.00
- E24Q (p.Glu24Gln), TOPMed rs1235063801, gnomAD rs1235063801, MetaLR 0.24, MetaSVM -0.78
- F25L (p.Phe25Leu), TOPMed rs1402008404, gnomAD rs1402008404, REVEL 0.26, MetaLR 0.09
- F25V (p.Phe25Val), gnomAD 18-31326605-T-G, REVEL 0.29, MetaLR 0.29
- F25S (p.Phe25Ser), gnomAD 18-31326606-T-C, REVEL 0.47, MetaLR 0.36
- F25F (p.Phe25Phe), rs1402008404, gnomAD 18-31326607-C-T, CADD 11.20
- R26* (p.Arg26Ter), rs397515639, ClinGen CA145276, ClinVar RCV000074351, ClinVar RCV000493440, CADD 36.00, Pathogenic
- R26Q (p.Arg26Gln), rs371750753, ClinGen CA8925744, ClinVar RCV002604482, ESP rs371750753, REVEL 0.07, MetaLR 0.07, Uncertain significance, not provided
- R26R (p.Arg26Arg), gnomAD 18-31326608-C-A, CADD 11.00
- R26P (p.Arg26Pro), gnomAD 18-31326609-G-C, REVEL 0.32, MetaLR 0.12
- I27N (p.Ile27Asn), TOPMed rs2071687475, REVEL 0.39, MetaLR 0.21
- I27S (p.Ile27Ser), TOPMed rs2071687475, MetaLR 0.20, MetaSVM -0.72
- I27I (p.Ile27Ile), gnomAD 18-31326613-C-A, CADD 9.03
- Q28L (p.Gln28Leu), NCI-TCGA Cosmic COSV5713, MetaLR 0.21, MetaSVM -0.70, Variant assessed as somatic; moderate impact.
- Q28K (p.Gln28Lys), gnomAD 18-31326614-C-A, REVEL 0.16, MetaLR 0.13
- V29I (p.Val29Ile), rs759853035, ClinGen CA402127491, ClinVar RCV002302912, ExAC rs759853035, REVEL 0.13, MetaLR 0.25, Uncertain significance, not provided
- V29L (p.Val29Leu), ExAC rs759853035, TOPMed rs759853035, gnomAD rs759853035, REVEL 0.20, MetaLR 0.29, Uncertain significance
- V29V (p.Val29Val), rs1250908280, gnomAD 18-31326876-A-G, CADD 10.20
- R30T (p.Arg30Thr), TOPMed rs1014740513, gnomAD rs1014740513, REVEL 0.17, MetaLR 0.17
- D31G (p.Asp31Gly), Ensembl rs2071688803
- D31H (p.Asp31His), ExAC rs765346933, gnomAD rs765346933, REVEL 0.31, MetaLR 0.33
- D31Y (p.Asp31Tyr), NCI-TCGA Cosmic COSV5713, MetaLR 0.21, MetaSVM -0.78, Variant assessed as somatic; moderate impact.
- D31N (p.Asp31Asn), gnomAD 18-31326880-G-A, REVEL 0.23, MetaLR 0.21
- D31D (p.Asp31Asp), gnomAD 18-31326882-T-C, CADD 11.00
- Y32C (p.Tyr32Cys), gnomAD rs1388945186, REVEL 0.23, MetaLR 0.17
- N33D (p.Asn33Asp), rs2071688855, ClinGen CA402127522, ClinVar RCV003362360, Ensembl rs2071688855, AlphaMissense 0.11, MetaLR 0.10, Uncertain significance, Inborn genetic diseases
- T34I (p.Thr34Ile), rs2071688880, ClinGen CA402127553, ClinVar RCV002617745, TOPMed rs2071688880, REVEL 0.06, MetaLR 0.09, Uncertain significance, not provided; Inborn genetic diseases
- T34S (p.Thr34Ser), TOPMed rs2071688880, gnomAD rs2071688880, MetaLR 0.06, MetaSVM -1.04, Uncertain significance
- K35I (p.Lys35Ile), rs1436775072, ClinGen CA402127566, ClinVar RCV003729312, TOPMed rs1436775072, REVEL 0.38, MetaLR 0.27, Uncertain significance, not provided
- K35R (p.Lys35Arg), TOPMed rs1436775072, gnomAD rs1436775072, MetaLR 0.16, MetaSVM -0.81, Uncertain significance
- N36T (p.Asn36Thr), TOPMed rs1482791506, gnomAD rs1482791506, REVEL 0.22, MetaLR 0.22
- N36K (p.Asn36Lys), gnomAD 18-31326897-T-A, REVEL 0.12, MetaLR 0.14
- N36N (p.Asn36Asn), gnomAD 18-31326897-T-C, CADD 9.60
- G37S (p.Gly37Ser), rs1414136866, gnomAD rs1414136866, REVEL 0.29, MetaLR 0.29, Variant assessed as somatic; moderate impact.
- G37V (p.Gly37Val), Ensembl rs2071688977, REVEL 0.34, MetaLR 0.35, Uncertain significance, not provided
- G37R (p.Gly37Arg), gnomAD 18-31326898-G-C, REVEL 0.26, MetaLR 0.24
- G37D (p.Gly37Asp), gnomAD 18-31326899-G-A, REVEL 0.26, MetaLR 0.20
- T38A (p.Thr38Ala), TOPMed rs1353460018, gnomAD rs1353460018, REVEL 0.19, MetaLR 0.23
- I39T (p.Ile39Thr), ExAC rs763066719, MetaLR 0.08, MetaSVM -0.99
- I39V (p.Ile39Val), rs775732796, ClinGen CA8925765, ClinVar RCV002797393, ExAC rs775732796, REVEL 0.06, MetaLR 0.09, Uncertain significance, not provided
- W41R (p.Trp41Arg), gnomAD rs1367270720, REVEL 0.39, MetaLR 0.27, Uncertain significance, Inborn genetic diseases
- H42R (p.His42Arg), ExAC rs750452440, TOPMed rs750452440, gnomAD rs750452440, REVEL 0.05, MetaLR 0.14, Uncertain significance, not provided
- H42Y (p.His42Tyr), rs767566563, NCI-TCGA Cosmic COSV9993, ExAC rs767566563, gnomAD rs767566563, REVEL 0.12, MetaLR 0.18, Variant assessed as somatic; moderate impact.
- S43A (p.Ser43Ala), ExAC rs755989089, gnomAD rs755989089, REVEL 0.08, MetaLR 0.11
- S43L (p.Ser43Leu), ExAC rs766242288, gnomAD rs766242288, REVEL 0.22, MetaLR 0.25
- S43S (p.Ser43Ser), rs753543956, gnomAD 18-31326918-A-G, CADD 5.64
- I44F (p.Ile44Phe), Ensembl rs1598698621
- I44T (p.Ile44Thr), TOPMed rs1409998656, gnomAD rs1409998656, REVEL 0.20, MetaLR 0.15, Uncertain significance, not provided
- I44V (p.Ile44Val), NCI-TCGA TCGA novel, Ensembl rs1598698621, MetaLR 0.09, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- R45* (p.Arg45Ter), rs1182196436, ClinGen CA402127750, ClinVar RCV000585694, ClinVar RCV001200414, CADD 35.00, Pathogenic
- R45Q (p.Arg45Gln), rs78287742, ClinGen CA8925772, ClinVar RCV001950288, 1000Genomes rs78287742, REVEL 0.17, MetaLR 0.32, Uncertain significance, not provided
- R45G (p.Arg45Gly), gnomAD 18-31326922-C-G, REVEL 0.36, MetaLR 0.29
- R46T (p.Arg46Thr), gnomAD 18-31326926-G-C, REVEL 0.56, MetaLR 0.53
- R46K (p.Arg46Lys), gnomAD 18-31326926-G-A, REVEL 0.37, MetaLR 0.53
- Q47K (p.Gln47Lys), NCI-TCGA TCGA novel, MetaLR 0.22, MetaSVM -0.79, Variant assessed as somatic; moderate impact.
- Q47Q (p.Gln47Gln), rs2144087826, gnomAD 18-31326930-G-A, CADD 4.26
- R49C (p.Arg49Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R49H (p.Arg49His), NCI-TCGA Cosmic COSV5713, Ensembl rs2144087833, REVEL 0.51, AlphaMissense 0.85, Variant assessed as somatic; moderate impact.
- R49L (p.Arg49Leu), rs2144087833, ClinGen CA402127826, ClinVar RCV002300306, AlphaMissense 0.85, MetaLR 0.48, Uncertain significance, not provided
- E50E (p.Glu50Glu), gnomAD 18-31326939-A-G, CADD 7.95
- W51L (p.Trp51Leu), NCI-TCGA Cosmic COSV9993, REVEL 0.51, MetaLR 0.58, Variant assessed as somatic; moderate impact.
- I52F (p.Ile52Phe), rs2144087836, ClinGen CA402127857, ClinVar RCV001943258, Ensembl rs2144087836, AlphaMissense 0.91, MetaLR 0.38, Uncertain significance, Inborn genetic diseases; not provided
- I52T (p.Ile52Thr), gnomAD rs1211990162, REVEL 0.36, MetaLR 0.30
- I52S (p.Ile52Ser), gnomAD 18-31326944-T-G, REVEL 0.52, MetaLR 0.41
- I52I (p.Ile52Ile), gnomAD 18-31326945-C-A, CADD 11.10
- K53S (p.Lys53Ser), rs2071689378, gnomAD 18-31326945-CA-C, CADD 28.00
- K53E (p.Lys53Glu), gnomAD 18-31326946-A-G, REVEL 0.25, MetaLR 0.31
- F54F (p.Phe54Phe), rs778383508, gnomAD 18-31326951-C-T, CADD 1.24
- A55S (p.Ala55Ser), rs747673709, ClinGen CA297689378, ClinVar RCV003700362, ExAC rs747673709, REVEL 0.22, MetaLR 0.32, Uncertain significance, not provided
- A55T (p.Ala55Thr), ExAC rs747673709, TOPMed rs747673709, gnomAD rs747673709, REVEL 0.31, MetaLR 0.36, Uncertain significance
- A55A (p.Ala55Ala), rs1191553339, gnomAD 18-31326954-A-G, CADD 6.24
- A56A (p.Ala56Ala), gnomAD 18-31326957-A-T, CADD 9.51
- A57T (p.Ala57Thr), rs1427235253, ClinGen CA402127890, NCI-TCGA Cosmic COSV5713, ClinVar RCV002954365, REVEL 0.14, MetaLR 0.21, Uncertain significance, not provided
- A57V (p.Ala57Val), TOPMed rs1024417334, MetaLR 0.22, MetaSVM -0.84
- C58* (p.Cys58Ter), rs2511042832, ClinGen CA402127901, ClinVar RCV003566041, Pathogenic
- C58S (p.Cys58Ser), TOPMed rs2071689510, MetaLR 0.25, MetaSVM -0.61
- C58R (p.Cys58Arg), gnomAD 18-31326961-T-C, REVEL 0.49, MetaLR 0.27
- C58Y (p.Cys58Tyr), gnomAD 18-31326962-G-A, REVEL 0.41, MetaLR 0.27
- R59C (p.Arg59Cys), rs2071689533, ClinGen CA402127905, ClinVar RCV003714651, REVEL 0.38, MetaLR 0.31, Uncertain significance, not provided
- R59G (p.Arg59Gly), TOPMed rs2071689533, MetaLR 0.30, MetaSVM -0.44
- R59H (p.Arg59His), rs757841646, ClinGen CA8925775, ClinVar RCV001984877, ExAC rs757841646, REVEL 0.37, MetaLR 0.35, Uncertain significance, not provided
- R59S (p.Arg59Ser), TOPMed rs2071689533, REVEL 0.29, MetaLR 0.27
- R59L (p.Arg59Leu), gnomAD 18-31326965-G-T, REVEL 0.35, MetaLR 0.24
- E60K (p.Glu60Lys), NCI-TCGA Cosmic COSV5713, MetaLR 0.69, MetaSVM 0.53, Variant assessed as somatic; moderate impact.
- E60A (p.Glu60Ala), gnomAD 18-31326968-A-C, REVEL 0.85, MetaLR 0.67
- G61G (p.Gly61Gly), rs1030004076, gnomAD 18-31326972-T-G, CADD 2.31
- E62V (p.Glu62Val), NCI-TCGA Cosmic COSV9993, MetaLR 0.22, MetaSVM -0.65, Variant assessed as somatic; moderate impact.
- E62K (p.Glu62Lys), gnomAD 18-31326973-G-A, REVEL 0.40, MetaLR 0.33
- E62D (p.Glu62Asp), gnomAD 18-31326975-A-C, REVEL 0.26, MetaLR 0.20
- D63H (p.Asp63His), gnomAD 18-31326976-G-C, REVEL 0.38, MetaLR 0.35
- D63G (p.Asp63Gly), gnomAD 18-31326977-A-G, REVEL 0.38, MetaLR 0.33
- D63D (p.Asp63Asp), rs2071689599, gnomAD 18-31326978-C-T, CADD 11.60
- D63E (p.Asp63Glu), gnomAD 18-31326978-C-A, REVEL 0.21, MetaLR 0.26
- N64T (p.Asn64Thr), gnomAD 18-31326980-A-C, REVEL 0.40, MetaLR 0.32
- N64N (p.Asn64Asn), rs777264346, gnomAD 18-31326981-C-T, CADD 9.76
- S65* (p.Ser65Ter), NCI-TCGA TCGA novel, CADD 37.00, Variant assessed as somatic; high impact.
- S65L (p.Ser65Leu), ExAC rs747573688, gnomAD rs747573688, REVEL 0.30, MetaLR 0.29
- S65P (p.Ser65Pro), Ensembl rs2144087884, MetaLR 0.21, MetaSVM -0.82
- S65S (p.Ser65Ser), gnomAD 18-31326984-A-C, CADD 6.44
- R67K (p.Arg67Lys), Ensembl rs2071689680, REVEL 0.15, MetaLR 0.17
- N68K (p.Asn68Lys), TOPMed rs2071689710, REVEL 0.25, MetaLR 0.21
- N68S (p.Asn68Ser), TOPMed rs951456106, MetaLR 0.33, MetaSVM -0.35
- N68D (p.Asn68Asp), gnomAD 18-31326991-A-G, REVEL 0.34, MetaLR 0.24
- P69T (p.Pro69Thr), NCI-TCGA Cosmic COSV5713, REVEL 0.32, MetaLR 0.29, Variant assessed as somatic; moderate impact.
- I70T (p.Ile70Thr), Ensembl rs982813480, MetaLR 0.41, MetaSVM -0.06
- I70V (p.Ile70Val), rs145119037, ClinGen CA8925778, ClinVar RCV002791336, ESP rs145119037, REVEL 0.18, MetaLR 0.18, Uncertain significance, not provided
- I70I (p.Ile70Ile), rs186238458, gnomAD 18-31326999-C-T, CADD 1.12
- A71T (p.Ala71Thr), rs1348931149, NCI-TCGA Cosmic COSV5713, gnomAD rs1348931149, REVEL 0.42, MetaLR 0.31, Uncertain significance, Inborn genetic diseases
- A71S (p.Ala71Ser), gnomAD 18-31327000-G-T, REVEL 0.30, MetaLR 0.36
- K72E (p.Lys72Glu), TOPMed rs1249896949, REVEL 0.37, MetaLR 0.26
- I73F (p.Ile73Phe), gnomAD rs1380198566, REVEL 0.40, MetaLR 0.36
- I73L (p.Ile73Leu), gnomAD rs1380198566, MetaLR 0.22, MetaSVM -0.75
- I73T (p.Ile73Thr), rs138930324, ClinGen CA8925795, ClinVar RCV003110451, ESP rs138930324, REVEL 0.50, MetaLR 0.35, Uncertain significance, not provided
- I73I (p.Ile73Ile), rs781492654, gnomAD 18-31328191-T-C, CADD 14.10
- H74R (p.His74Arg), ESP rs149439494, ExAC rs149439494, TOPMed rs149439494, gnomAD rs149439494, REVEL 0.11, MetaLR 0.06
- H74Q (p.His74Gln), gnomAD 18-31328194-C-A, REVEL 0.12, MetaLR 0.10
- S75* (p.Ser75Ter), rs2511043841, ClinGen CA402128025, ClinVar RCV003572354, Pathogenic
- A78D (p.Ala78Asp), NCI-TCGA Cosmic COSV5713, Variant assessed as somatic; moderate impact.
- A78S (p.Ala78Ser), NCI-TCGA Cosmic COSV5713, MetaLR 0.18, MetaSVM -0.81, Variant assessed as somatic; moderate impact.
- A78T (p.Ala78Thr), ExAC rs770122916, gnomAD rs770122916, REVEL 0.12, MetaLR 0.18
- A78V (p.Ala78Val), gnomAD 18-31328205-C-T, REVEL 0.22, MetaLR 0.22
- A78A (p.Ala78Ala), rs780552898, gnomAD 18-31328206-T-C, CADD 10.70
- A79T (p.Ala79Thr), gnomAD rs1275307469, REVEL 0.04, MetaLR 0.12
- A79S (p.Ala79Ser), gnomAD 18-31328207-G-T, REVEL 0.01, MetaLR 0.10
- N80H (p.Asn80His), TOPMed rs2071698370, MetaLR 0.20, MetaSVM -0.70
- N80T (p.Asn80Thr), TOPMed rs1008682996, gnomAD rs1008682996, REVEL 0.18, MetaLR 0.16, Uncertain significance, not provided
- N80N (p.Asn80Asn), gnomAD 18-31328212-C-T, CADD 8.35
- Q81* (p.Gln81Ter), rs1598699465, ClinGen CA402128063, ClinVar RCV001092834, Ensembl rs1598699465, CADD 36.00, Pathogenic
- Q81H (p.Gln81His), rs74368609, ClinGen CA8925800, ClinVar RCV000969694, 1000Genomes rs74368609, REVEL 0.34, MetaLR 0.25, Benign, not provided
- Q81K (p.Gln81Lys), Ensembl rs1598699465, MetaLR 0.16, MetaSVM -0.99, Pathogenic
- Q82R (p.Gln82Arg), rs2511043868, ClinGen CA402128072, ClinVar RCV002942766, Uncertain significance, not provided
Public DSG1 analysis runs
- DSG1 analysis run — DSG1 (1,651 variants) — completed 2026-08-22